Frontotemporal lobar degeneration.
Grossman M, Seeley WW, Boxer AL, Hillis AE, Knopman DS, Ljubenov PA, Miller B, Piguet O, Rademakers R, Whitwell JL, Zetterberg H, van Swieten JC.
Nat Rev Dis Primers. 2023 Aug 10;9(1):40. doi: 10.1038/s41572-023-00447-0.
HnRNP Pathologies in Frontotemporal Lobar Degeneration.
Jiang X, Gatt A, Lashley T.
Cells. 2023 Jun 15;12(12):1633. doi: 10.3390/cells12121633.
Frontotemporal Lobar Degeneration.
Premi E, Padovani A, Borroni B.
Adv Exp Med Biol. 2012;724:114-27. doi: 10.1007/978-1-4614-0653-2_9.
Immunological signatures in frontotemporal lobar degeneration.
Sirkis DW, Bonham LW, Karch CM, Yokoyama JS.
Curr Opin Neurol. 2019 Apr;32(2):272-278. doi: 10.1097/WCO.0000000000000665.
Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.
Carlos AF, Josephs KA.
J Neurol. 2022 Aug;269(8):4030-4054. doi: 10.1007/s00415-022-11073-3. Epub 2022 Mar 23.
Neurotransmitter deficits from frontotemporal lobar degeneration.
Murley AG, Rowe JB.
Brain. 2018 May 1;141(5):1263-1285. doi: 10.1093/brain/awx327.
Review: Neuropathology of non-tau frontotemporal lobar degeneration.
Neumann M, Mackenzie IRA.
Neuropathol Appl Neurobiol. 2019 Feb;45(1):19-40. doi: 10.1111/nan.12526.
Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.
Li YQ, Tan MS, Yu JT, Tan L.
Mol Neurobiol. 2016 Nov;53(9):6091-6105. doi: 10.1007/s12035-015-9507-5. Epub 2015 Nov 4.
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations.
Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD.
Lancet Neurol. 2022 Mar;21(3):258-272. doi: 10.1016/S1474-4422(21)00341-0.
Measuring social cognition in frontotemporal lobar degeneration: a clinical approach.
Magno MA, Canu E, Agosta F, Filippi M.
J Neurol. 2022 Apr;269(4):2227-2244. doi: 10.1007/s00415-021-10889-9. Epub 2021 Nov 19.
